Cureus · 2026
Dapagliflozin-Based Therapies in Patients With Type 2 Diabetes Mellitus in an Outpatient Real-World Setting Across India: The DAPATURN Study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chawla Rajeev, T K Sabeer, Singh K P, Mehta Ashwani, Chattopadhyay Mounam, Rakshit Kaushik M, Motiramani Nikhil, Philip Rajeev, Shinde Amber C, K Sowmiya M, Revenkar Santosh, Patel Kamlesh
Аннотация
AIM: Determination of usage patterns and clinical profile of patients receiving dapagliflozin and its combinations in outpatient settings across India.
METHODS: An observational, cross-sectional study was conducted across 661 sites in four zones of India from March to December 2024. Baseline demographics, comorbidities, and used dapagliflozin formulations (dual or triple fixed-dose combination (FDC)) were recorded to analyze usage patterns.
RESULT: A total of 34,443 patients were enrolled from North (n = 8,035), South (n = 8,205), East (n = 11,143), and West (n = 7,060) India, with a mean age of 54.94 ± 11.35 years. Mean glycemic hemoglobin (HbA1c) and body mass index were 8.53 ± 1.56% and 27.21 ± 4.93 kg/m², respectively. The most common formulation was dapagliflozin + sitagliptin + metformin triple FDC (n = 11,657, 33.84%), followed by dapagliflozin + sitagliptin dual FDC (n = 9,940, 28.86%) and dapagliflozin + metformin dual FDC (n = 1,808, 5.24%). Dapagliflozin + sitagliptin was most used in patients with hypertension (n = 1045, 34.30%), dyslipidemia (n = 500, 35.06%), chronic kidney disorder (CKD) (n = 54, 36.99%), heart failure (HF) (n = 52, 35.86%), hypertension + dyslipidemia (n = 225, 31.91%), and atherosclerotic cardiovascular disease (ASCVD) + dyslipidemia (n = 124, 38.15%). Triple FDC use was highest in ASCVD (n = 782, 33.56%) and HF + CKD (n = 15, 50%). In both HbA1c groups (<8.5% vs. >8.5%), dapagliflozin + sitagliptin (n = 6,332, 31.5%, vs. n = 3,608, 25.16%) and triple FDC dapagliflozin + sitagliptin+ metformin (n = 6,456, 32.11%, vs. n = 5,200, 36.27%) were most used. Dapagliflozin + sitagliptin use increased with diabetes duration (<1 year: n = 420, 23.4%, to >10 years, n = 1,422, 39.45%), while triple FDC preference remained high from <1 year (n = 637, 35.49%) to 10 years (n = 4,192, 34.96%).
CONCLUSIONS: This study highlights real-world dapagliflozin use in India, showing that dapagliflozin-based FDCs are widely adopted across diverse patient groups.
METHODS: An observational, cross-sectional study was conducted across 661 sites in four zones of India from March to December 2024. Baseline demographics, comorbidities, and used dapagliflozin formulations (dual or triple fixed-dose combination (FDC)) were recorded to analyze usage patterns.
RESULT: A total of 34,443 patients were enrolled from North (n = 8,035), South (n = 8,205), East (n = 11,143), and West (n = 7,060) India, with a mean age of 54.94 ± 11.35 years. Mean glycemic hemoglobin (HbA1c) and body mass index were 8.53 ± 1.56% and 27.21 ± 4.93 kg/m², respectively. The most common formulation was dapagliflozin + sitagliptin + metformin triple FDC (n = 11,657, 33.84%), followed by dapagliflozin + sitagliptin dual FDC (n = 9,940, 28.86%) and dapagliflozin + metformin dual FDC (n = 1,808, 5.24%). Dapagliflozin + sitagliptin was most used in patients with hypertension (n = 1045, 34.30%), dyslipidemia (n = 500, 35.06%), chronic kidney disorder (CKD) (n = 54, 36.99%), heart failure (HF) (n = 52, 35.86%), hypertension + dyslipidemia (n = 225, 31.91%), and atherosclerotic cardiovascular disease (ASCVD) + dyslipidemia (n = 124, 38.15%). Triple FDC use was highest in ASCVD (n = 782, 33.56%) and HF + CKD (n = 15, 50%). In both HbA1c groups (<8.5% vs. >8.5%), dapagliflozin + sitagliptin (n = 6,332, 31.5%, vs. n = 3,608, 25.16%) and triple FDC dapagliflozin + sitagliptin+ metformin (n = 6,456, 32.11%, vs. n = 5,200, 36.27%) were most used. Dapagliflozin + sitagliptin use increased with diabetes duration (<1 year: n = 420, 23.4%, to >10 years, n = 1,422, 39.45%), while triple FDC preference remained high from <1 year (n = 637, 35.49%) to 10 years (n = 4,192, 34.96%).
CONCLUSIONS: This study highlights real-world dapagliflozin use in India, showing that dapagliflozin-based FDCs are widely adopted across diverse patient groups.